Platinib medical insurance price in 2024

Pralsetinib is an oral, small molecule inhibitor of tyrosine kinase receptors encoded by the proto-oncogene RET (rearranged during transfection), which is mutated or altered in several cancers, including 1% to 2% of non-small cell lung cancer (NSCLC) , up to 70% of medullary thyroid carcinomas, and approximately 10% of other thyroid cancers. Platinib was found to be a potent inhibitor of cell growth and proliferation in tumor cell lines and experimental tumor models with RET mutations or RET gene fusions.

In open-label trials of platinib in patients with advanced or metastatic medullary thyroid cancer and NSCLC with RET alterations, objective response rates ranged from 56% to 85%. Platinib received accelerated approval for use in the United States in 2020 and subsequently received full approval. It has shown efficacy in several other solid tumors harboring RET gene alterations. Prasetinib is available in 100 mg capsules under the brand name Gavreto. The recommended dose for adults and children 12 years or older is 400 mg once daily. Side effects are common and include dry mouth, diarrhea, constipation, abdominal pain, nausea, systemic arterial hypertension, myalgia, fever, cough, edema, anemia, neutropenia, and increased serum creatinine, uric acid, and transaminases levels.

Platinib The original drug has been launched in China. Unfortunately, it has not been included in the medical insurance. It can be purchased in domestic hospitals or pharmacies. The common packaging specifications are: 100mg 60 pills and 100mg 120 pills. However, the price is relatively high. A box may exceed 20,000 yuan. In some areas, the price is even as high as 60,000 yuan. The price is very expensive. The first generic drug of Platinib has been developed overseas. Its ingredients are roughly the same as the original drug on the market. The price of 120 pills produced in Laos is about more than 4,000 yuan (the price may change with the exchange rate), which is relatively cheap.